Innate Pharma Files Routine 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Sep 9, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Sep 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, regulatory-update, foreign-private-issuer
TL;DR
Innate Pharma filed a 6-K on 9/9/24. Standard foreign issuer report, no major news.
AI Summary
On September 9, 2024, Innate Pharma SA filed a Form 6-K. This report is a submission under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, indicating it is a report of a foreign private issuer. The filing does not contain specific financial figures or operational updates but serves as a routine disclosure.
Why It Matters
This filing is a standard disclosure for foreign private issuers, providing transparency to investors about their regulatory compliance and reporting status with the SEC.
Risk Assessment
Risk Level: low — The filing is a routine procedural document for a foreign private issuer and does not contain new material information that would typically impact risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- September 9, 2024 (date) — Filing Date
- 001-39084 (other) — SEC File Number
FAQ
What type of filing is this Form 6-K for Innate Pharma SA?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What is the filing date of this report?
The report was filed on September 9, 2024.
What is the SEC file number for Innate Pharma SA?
The SEC file number for Innate Pharma SA is 001-39084.
Does Innate Pharma SA file annual reports under Form 20-F or Form 40-F?
Innate Pharma SA indicates it files annual reports under Form 20-F.
Where is Innate Pharma SA's principal executive office located?
Innate Pharma SA's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2024-09-09 06:13:15
Filing Documents
- a6k-iphx240909.htm (6-K) — 9KB
- exhibit991-240909.htm (EX-99.1) — 24KB
- 0001598599-24-000059.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date September 9, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive Officer